2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Thrombocytopenia
6
Leukemia
4
Hematologic Neoplasms
3
Hematologic Diseases
3
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Lymphoma
2
Leukemia, Myeloid, Acute
2
Venous Thromboembolism
1
Transfusion Reaction
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Multiple Sclerosis
1
Motor Activity
1
Lymphoma, T-Cell
1
Lymphoma, B-Cell
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Biphenotypic, Acute
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
fludarabine phosphate
60
Cyclophosphamide
60
Busulfan
43
Cyclosporine
41
Mycophenolic Acid
40
Peripheral Blood Stem Cell Transplantation
39
Cytarabine
36
Whole-Body Irradiation
34
Antilymphocyte Serum
29
Filgrastim
26
Tacrolimus
24
Methotrexate
24
fludarabine
23
Cord Blood Stem Cell Transplantation
22
Radiotherapy
21
Melphalan
20
Etoposide
18
Methylprednisolone
15
Azacitidine
14
Granulocyte Colony-Stimulating Factor
13
Idarubicin
12
Daunorubicin
11
Thiotepa
10
sargramostim
8
Cyclosporins
8
Clofarabine
7
Arsenic Trioxide
7
Transplantation
6
Topotecan
6
Mitoxantrone
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Anemia, Refractory, with Excess of Blasts
×
Platelet Transfusion
×
Clear all
NCT01615146
2015-09-02
OPTIMAL
Ottawa Hospital Research Institute
Phase NA
Terminated
9 enrolled